1-8 of 8
Megan Braunlin
Close
Sort by
Journal Articles

Real -World Outcomes for Relapsed or Refractory Multiple Myeloma Patients Treated with Lenalidomide and Daratumumab Sparing Triplet Regimens: A United States Retrospective Cohort Study

Megan Braunlin, Rani Najdi, Mukta Arora, Amy Kimball, Rong Tilney, Ian McFadden
Journal: Blood
Blood (2023) 142 (Supplement 1): 4705.
https://doi.org/10.1182/blood-2023-184525
Published: 2023
Journal Articles

Outcomes of Triple-Class (proteasome inhibitor, immunomodulator, CD38 monoclonal antibody) Exposed Relapsed or Refractory Multiple Myeloma (RRMM) in United States (US) Real-World Practice

Christopher Kim, Megan Braunlin, Bhakti Mehta, Rebecca Payne
Journal: Blood
Blood (2021) 138 (Supplement 1): 3042.
https://doi.org/10.1182/blood-2021-145588
Published: 2021
Journal Articles

A Temporal and Multinational Assessment of Acute Myeloid Leukemia (AML) Cancer Incidence, Survival, and Disease Burden

Laura J. Anderson, Mariam S. Girguis, Ju-Hyeun Kim, Jitesh B. Shewale, Megan Braunlin, Winifred Werther, Juliana E. Hidalgo-Lopez, Faraz Zaman, Christopher Kim
Journal: Blood
Blood (2021) 138 (Supplement 1): 4124.
https://doi.org/10.1182/blood-2021-146251
Published: 2021
Journal Articles

Progression Free Survival of Relapsed or Refractory Multiple Myeloma (RRMM) after Failure of Three Prior Lines of Therapy in United States (US) Real-World Practice

Christopher Kim, PhD, Megan Braunlin, MPH, Rajesh Belani, MD, John Travis Wheeling, MPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–24.
https://doi.org/10.1182/blood-2020-140549
Published: 2020
Journal Articles

Trends in the Multiple Myeloma Treatment Landscape: A United States Analysis of Oscer Electronic Health Record Data 2011-2019

Megan Braunlin, MPH, Rajesh Belani, MD, Jacqueline Buchanan, John Travis Wheeling, MPH, Christopher Kim, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4722.
https://doi.org/10.1182/blood-2019-125972
Published: 2019
Journal Articles

Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting

Shaji K. Kumar, MD, Alan Fu, PhD MPH, Khalid Mezzi, Megan Braunlin, Christopher Kim, PhD, Karim Iskander, Ruben Niesvizky, MD, Sundar Jagannath, MD, Ralph Boccia, MD, Noopur Raje, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3253.
https://doi.org/10.1182/blood-2018-99-113519
Published: 2018
Journal Articles

Identifying Ultra-High Risk Smoldering Multiple Myeloma

Theresia Akhlaghi, BS, Even H Rustad, MD, Venkata D Yellapantula, Neha Korde, MD, Sham Mailankody, MBBS, Nikoletta Lendvai, MD PhD, Alexander M. Lesokhin, MD, Hani Hassoun, MD, Sergio Giralt, MD, Heather J. Landau, MD, Eric L. Smith, MD PhD, Gunjan L. Shah, MD, Michael Scordo, MD, David J. Chung, MD PhD, Khalid Mezzi, Monica Khurana, Megan Braunlin, Winifred Werther, Ola Landgren, MD PhD, Malin Hultcrantz, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3192.
https://doi.org/10.1182/blood-2018-99-109709
Published: 2018
Journal Articles

Cardiac Events in Real-World Multiple Myeloma Patients Treated with Carfilzomib: A Retrospective Claims Database Analysis

Ajai Chari, MD, Sanjay K. Aggarwal, Khalid Mezzi, Kenneth Wang, Christopher Kim, Shao Zhu, Megan Braunlin, Winifred Werther, Joseph Mikhael, MD
Journal: Blood
Blood (2016) 128 (22): 3319.
https://doi.org/10.1182/blood.V128.22.3319.3319
Published: 2016